Pfizer's smoking-cessation treatment Chantix might not increase the risk of heart attack and other serious heart conditions, as was reported in a 2011 study, according to a review that looked at data on 9,232 people treated for three months. Researcher Judith Prochaska said the first study was misleading because "findings were inflated, and they were just focusing on that relative risk." Only 0.63% of 5,431 individuals developed a serious heart problem.
Chantix might not increase heart risk, review shows
SmartBrief Job Listings for Health Care
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan